Artiva Biotherapeutics opened lower at $4.05, compared with its previous close of $4.07. In the last trading session, the stock traded between $3.93 and $4.10. It showed a downward intraday trend.
An investment of $100 made 3 years ago in Artiva Biotherapeutics is now worth
$ 33.05
Resulting in a loss of
$ 66.95 (66.95%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.10 (-2.56%)
Day High
$4.10
Day Low
$3.93
Day Open
$4.05
Prev Close
$4.07
Volume
13,02,575
1W Return
-6.06%
1M Return
-41.42%
3M Return
-66.32%
6M Return
-62.58%
1Y Return
10.47%
Market Cap ($ Mn)
196
PE Ratio
-
PB Ratio
1.55
PEG Ratio
-
ROE
-56.39%
ROCE
-56.81%
EPS (TTM)
-
1 Week
-6.06%
1 Month
-41.42%
3 Months
-66.32%
6 Months
-62.58%
9 Months
3.01%
Artiva Biotherapeutics estimates $10M-$15M in AlloNK trial termination costs
Artiva Biotherapeutics estimates $10 million to $15 million in contract termination costs for AlloNK trials. Workforce reduction costs are projected between $17 million and $20 million. Total estimated restructuring expenses range from $27 million to $35 million.
3 days agoArtiva Biotherapeutics to present AlloNK data at ACR Convergence 2026
Artiva Biotherapeutics will present updated Phase 2a data on AlloNK® at ACR Convergence 2026. Oral presentation covers efficacy in 34 patients across RA, Sjögren disease, and systemic sclerosis. Data shows B-cell depletion comparable to CD19 CAR T therapies with favorable tolerability. Company plans Phase 3 registrational trial initiation in second half of 2026.
1mo agoArtiva Biotherapeutics files prospectus to offer $400m in securities
Artiva Biotherapeutics filed an SEC prospectus to offer up to $400 million in securities. This shelf registration allows flexible capital raising for future needs. The filing underscores the company's focus on securing financial resources for growth and operational stability.
3mo agoArtiva Biotherapeutics grants 288,800 RSUs to 17 new employees
Artiva Biotherapeutics granted 288,800 restricted stock units to 17 new employees under its 2025 Inducement Plan. The grants, effective July 14, 2026, vest over four years with quarterly vesting dates. These inducement grants were approved by the Compensation Committee in accordance with Nasdaq listing Rule 5635(c)(4).
3mo agoArtiva Biotherapeutics to present at H.C. Wainwright conference
Artiva Biotherapeutics management will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. The company plans to initiate a Phase 3 registrational trial for its lead program AlloNK in refractory rheumatoid arthritis in 2026. The webcast will be available for replay for 90 days.
4mo agoNeedham reiterates Buy on Artiva Biotherapeutics
Needham analyst Gil Blum has reaffirmed a Buy rating for Artiva Biotherapeutics, maintaining a price target of $41. The stock trades on NASDAQ under the ticker symbol ARTV.
5mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 3 years ago in Artiva Biotherapeutics is now worth
$ 33.05
Resulting in a loss of
$ 66.95 (66.95%)
Note: Past profits do not guarantee future returns.
